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Introduction 
Patients with schizophrenia take antipsychotic drugs chronically 
to manage their psychotic symptoms. It is thus of great impor-
tance to understand the effects of long-term antipsychotic treat-
ment on brain functions and related psychological functions to 
better understand the therapeutic and side effects of antipsy-
chotic medications. Many clinical and preclinical studies have 
reported that chronic administration of antipsychotic drugs of-
ten cause either an augmentation or decrease of some of the 
acute effects of a drug, termed antipsychotic sensitization and 
tolerance, respectively (Remington and Kapur, 2010; Samaha 
et al., 2007, 2008; Zhang and Li, 2012). These two phenomena 
can manifest at multiple levels, including neurotransmitter re-
lease, changes in neuroreceptor levels, receptor-mediated sec-
ond messenger activities, cell electrophysiology, and behaviors, 
and which can be clinically relevant. For example, haloperidol-
induced sensitization has been linked to the gradual develop-
ment of some extrapyramidal motor side effects (Turrone et al., 
2005), increased dopamine supersensitivity (Samaha et al., 2007), 
and the progressive improvement of psychosis (Agid et al., 2003). 
One important issue in the field of antipsychotic sensitiza-
tion and tolerance is to identify the critical factors that deter-
mine the specific patterns of the long-term effects of chronic an-
tipsychotic drug treatment. Among many potential factors, two 
seem prominent. One is the drug administration schedule (e.g. 
intermittent vs continuous), as many studies have shown that 
continuous or frequent drug administration produces some de-
gree of tolerance, while more intermittent injections can result 
in sensitization (Remington and Kapur, 2010). The second factor 
is the specific drug type (e.g. clozapine vs olanzapine). In recent 
years, we have shown that under the same intermittent drug ad-
ministration schedule, haloperidol, olanzapine, risperidone, and 
asenapine all produce a sensitization-like effect in their suppres-
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Abstract 
The present study investigated how repeated administration of aripiprazole (a novel antipsychotic drug) alters its behavioral effects in two be-
havioral tests of antipsychotic activity and whether this alteration is correlated with an increase in dopamine D2 receptor function. Male adult 
Sprague-Dawley rats were first repeatedly tested with aripiprazole (3, 10 and 30 mg/kg, subcutaneously (sc)) or vehicle in a conditioned avoid-
ance response (CAR) test or a phencyclidine (PCP) (3.20 mg/kg, sc)-induced hyperlocomotion test daily for five consecutive days. After 2–3 days 
of drug-free retraining or resting, all rats were then challenged with aripiprazole (1.5 or 3.0 mg/kg, sc). Repeated administration of aripiprazole 
progressively increased its inhibition of avoidance responding and PCP-induced hyperlocomotion. More importantly, rats previously treated with 
aripiprazole showed significantly lower avoidance response and lower PCP-induced hyperlocomotion than those previously treated with vehicle 
in the challenge tests. An increased sensitivity to quinpirole (a selective D2/3 agonist) in prior aripiprazole-treated rats was also found in the quin-
pirole-induced hyperlocomotion test, suggesting an enhanced D2/3-mediated function. These findings suggest that aripiprazole, despite its dis-
tinct receptor mechanisms of action, induces a sensitization effect similar to those induced by other antipsychotic drugs and this effect may be 
partially mediated by brain plasticity involving D2/3 receptor systems. 
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sion of the conditioned avoidance response (CAR) and phency-
clidine (PCP)-induced hyperlocomotion (two independent be-
havioral effects predictive of antipsychotic activity) (Feng et al., 
2013; Li et al., 2012; Mead and Li, 2010; Qiao et al., 2013; Qin et 
al., 2013; Swalve and Li, 2012; Zhang and Li, 2012). However, clo-
zapine produces a tolerance-like effect in these tests (Feng et al., 
2013; Li et al., 2010; Qiao et al., 2013). These findings suggest 
that antipsychotic sensitization and tolerance is also a drug spe-
cific phenomenon, in addition to its schedule-dependent feature. 
The present study was intended to further examine the drug-
specificity issue of antipsychotic sensitization and tolerance by 
determining what type of repeated effect (sensitization or tol-
erance) that aripiprazole would induce and whether such an ef-
fect is associated with changes in dopamine D2 receptor system 
(Gao and Li, 2013). We are interested in aripiprazole because it 
is a new antipsychotic drug with a unique pharmacological pro-
file distinct from the conventional and atypical antipsychotics 
(Mamo et al., 2007). It is a partial 5-hydroxytryptamine 1A (5-
HT1A) receptor agonist and 5-HT2A receptor antagonist, but un-
like other antipsychotics, which are potent D2 receptor antago-
nists, aripiprazole has partial agonist activity on these receptors 
(Bortolozzi et al., 2007; Burris et al., 2002; Jordan et al., 2002). 
Its long-term effects in animal behavioral tests of antipsychotic 
drugs have never been assessed and the behavioral pattern (i.e. 
sensitization or tolerance) it would induce is not known. 
In this study, we employed a paradigm that has been vali-
dated in our previous CAR and PCP-induced hyperlocomotion 
work. This paradigm consists of two phases of drug effect as-
sessment: an induction phase and an expression phase (Feng 
et al., 2013; Li et al., 2010, 2012; Mead and Li, 2010; Qiao et al., 
2014; Shu et al., 2014; Swalve and Li, 2012, Zhang and Li, 2012). 
In the induction phase, rats are repeatedly treated with an anti-
psychotic drug or vehicle for a certain number of days (e.g. five 
or seven days), and the drug’s suppressive effect on avoidance 
response and PCP-induced hyperlocomotion is recorded daily. 
In the expression phase, all rats are given a challenge dose of 
the drug and tested for avoidance response and PCP-induced 
hyperlocomotion. Two measures are taken to index the poten-
tial sensitization or tolerance effect of the drug. The first index of 
antipsychotic sensitization/tolerance is obtained from the induc-
tion phase and is revealed through a within-subjects comparison, 
in which the behavioral effect of a drug treatment is stronger/
weaker on the last treatment day than the first day (i.e. a com-
parison between days 1 and 5). The second index is obtained 
from the expression phase and is provided by a between-sub-
jects comparison, in which the behavioral response of drug-pre-
treated animals to a challenge dose of an antipsychotic drug is 
compared to the response of vehicle- pretreated control animals. 
Here, antipsychotic sensitization/ tolerance is demonstrated by 
increased/decreased sensitivity to the drug challenge in drug-
pretreated animals relative to those pretreated with vehicle. In 
addition, because our recent work suggests that risperidone-in-
duced sensitization in the conditioned avoidance response test 
is correlated with an increase in D2-mediated motor activity, as 
assessed in the quinipirole (a dopamine D2/3 receptor agonist)-
induced hyperlocomotion test (Gao and Li, 2013), we also ex-
amined whether repeated aripiprazole would also cause a sim-
ilar change in D2 receptor function. 
Materials and method 
Animals 
Adult male Sprague-Dawley rats (226–250 g upon arrival, 
Charles River, Portage, Michigan, USA) were housed two per 
cage, in transparent polycarbonate cages (48.3×26.7×20.3 cm, 
or 39.5×34.6×21.3 cm) under 12-hour light/dark conditions (light 
on between 06:00–18:00). Room temperature was maintained at 
22±1°C with a relative humidity of 45–60%. Food and water was 
available ad libitum. Rats were allowed at least five days of habit-
uation to the animal facility before being used in experiments. All 
behavioral tests took place between 09:00–17:00 in the light cy-
cle. All experimental treatments and procedures were approved 
by the Institutional Animal Care and Use Committee at the Uni-
versity of Nebraska-Lincoln. 
Drugs and choice of doses 
Aripiprazole (gift from the National Institute of Mental Health 
drug supply program) was dissolved in a mixed double-distilled 
water solution containing 30% (v/v) dimethylformamide and 2% 
(v/v) glacial acetic acid. Doses of aripiprazole (3, 10 and 30 mg/ 
kg) were determined based on our previous studies (Li et al., 2005) 
and reports in the literature (Carli et al., 2011; Cosi et al., 2006; Li 
et al., 2004; Natesan et al., 2006). These doses of aripiprazole give 
rise to 71%, 85%, and 84% D2 occupancies, respectively, at one 
hour post injection (Natesan et al., 2006), but do not cause cata-
lepsy (Hirose et al., 2004). The dose of PCP (3.20 mg/kg) was cho-
sen based on our previous work (Shu et al., 2014; Sun et al., 2009, 
2010; Zhang and Li, 2012; Zhao et al., 2012). This dose of PCP is 
shown to induce a robust hyperlocomotion effect without caus-
ing severe stereotypy (Gleason and Shannon, 1997; Kalinichev et 
al., 2008). The chosen quinpirole dose (1.0 mg/kg) targets post-
synaptic D2/3 receptors and causes an increase in motor activity 
(Koller et al., 1987; Luque-Rojas et al., 2013; Nakamura et al., 1994; 
Prosser et al., 1989). This dose of quinpirole was chosen based on 
the similar studies from our laboratory (Gao and Li, 2013; Qiao et 
al., 2014). Quinpirole was dissolved in 0.9% saline. All drugs were 
administrated subcutaneously (sc) at 1.0 ml/kg. 
Apparatus 
Two-way avoidance conditioning apparatus. Eight identical two-
way shuttle boxes custom designed and manufactured by Med 
Associates (St. Albans, Vermont, USA) were used. Each box was 
housed in a ventilated, sound-insulated isolation cubicle (96.52 
cm W×35.56 cm D×63.5 cm H). Each box was 64 cm long, 30 
cm high (from grid floor), and 24 cm wide, and was divided 
into two equal-sized compartments by a partition with an arch 
style doorway (15 cm high×9 cm wide at base). A barrier (4 cm 
high) was placed between the two compartments, so the rats 
had to jump from one compartment to the other. The grid floor 
consisted of 40 stainless-steel rods with a diameter of 0.48 cm, 
spaced 1.6 cm apart center to center, through which a scram-
bled footshock (unconditioned stimulus, US, 0.8 mA, maximum 
duration: 5 s) was delivered by a constant current shock gener-
ator (Model ENV-410B) and scrambler (Model ENV-412). The rat 
location and crossings between compartments were monitored 
by a set of 16 photobeams (ENV-256-8P) affixed at the bottom 
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of the box (3.5 cm above the grid floor). Illumination was pro-
vided by two houselights mounted at the top of each compart-
ment. The conditioned stimulus (CS), i.e. 76 dB white noise) was 
produced by a speaker (ENV 224 AMX) mounted on the ceiling 
of the cubicle, centered above the shuttle box. Background noise 
(approximately 74 dB) was provided by a ventilation fan affixed 
at the top corner of each isolation cubicle. All training and test-
ing procedures were controlled by Med Associates programs 
running on a computer. 
Locomotor activity monitoring apparatus. The motor activity test-
ing apparatus is described in detail before (Feng et al., 2013; 
Sun et al., 2009; Zhao and Li, 2012). Sixteen activity boxes were 
housed in a quiet room. The boxes were 48.3×26.7×20.3 cm 
transparent polycarbonate cages, which were similar to the home 
cages but were each equipped with a row of six photocell beams 
(7.8 cm between two adjacent photobeams) placed 3.2 cm above 
the floor of the cage. A computer with recording software (Aero 
Apparatus Sixbeam Locomotor System v1.4, Toronto, Canada) 
was used to detect the disruption of the photocell beams and 
recorded the number of beam breaks. All experiments were run 
during the light cycle. 
Experiment 1: Effect of repeated aripiprazole 
treatment on avoidance responding 
This experiment examined whether repeated aripiprazole treat-
ment induces a sensitization or tolerance effect in the CAR 
model and whether this sensitization or tolerance is accompa-
nied by dopamine receptor changes. The experiment was com-
prised of the following three phases: Phase 1: avoidance training 
and five days of repeated aripiprazole testing; phase 2: aripipra-
zole challenge test; and phase 3: quinpirole-induced hyperloco-
motion test. Figure 1 summarizes the entire experimental proce-
dure and groups at different phases of the experiment. 
Phase 1: Avoidance training in CAR and five days of repeated ar-
ipiprazole testing. Forty rats were first habituated to the CAR 
boxes for two days (30 min/day). They were then trained to make 
avoidance responding for 10 days/sessions. Each session con-
sisted of 30 trials. Every trial started by presenting a white noise 
(CS) for 10 s, followed by a continuous scrambled foot shock (0.8 
mA, US, maximum duration=5 s) on the grid floor. If a subject 
moved from one compartment into the other within the 10 s of 
CS presentation, it avoided the shock and this shuttling response 
was recorded as avoidance. If the rat remained in the same com-
partment for more than 10 s and made a crossing upon receiving 
the footshock, this response was recorded as escape. If the rat 
did not respond during the entire 5 s presentation of the shock, 
the trial was terminated and the intertrial intervals started. The 
total number of avoidance responses was recorded for each ses-
sion. Intertrial intervals varied randomly between 30 and 60 s. 
At the end of the training session, 36 rats reached the train-
ing criterion (≥70% avoidance in each of the last two sessions). 
They were first matched on avoidance performance on the last 
training day (i.e. pre-drug) to create blocks of rats (n=4 rats/
block) that were approximately equal in performance. Within 
Figure 1. A schematic illustration of the experimental procedure and groups in experiment 1 (conditioned avoidance response (CAR) model) and 
experiment 2 (phencyclidine (PCP) model). ARI: aripiprazole; CS: conditioned stimulus; QUI: quinpirole; US: unconditioned stimulus; VEH: vehicle.  
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each block, they were then randomly assigned to one of four 
groups: aripiprazole 3 mg/kg (ARI 3, n=9), aripiprazole 10 mg/
kg (ARI 10, n=9), aripiprazole 30 mg/kg (ARI 30, n=9) and ve-
hicle (VEH, n=9), and tested daily under the CS-only (no shock, 
30 trials/session) condition for five consecutive days, following 
the same procedure as employed before (Feng et al., 2012, 2013; 
Swalve and Li, 2012; Zhang and Li, 2012). On each test day, rats 
were first injected with aripiprazole or vehicle (mixed double-
distilled water solution containing 30% (v/v) dimethylformamide 
and 2% (v/v) glacial acetic acid), 60 min later, they were placed 
in the CAR boxes and tested. 
Phase 2: Aripiprazole challenge test. One day after the last (5th) 
aripiprazole test day, all rats were retrained drug-free for one 
session under the CS-only (no shock) condition, followed by an-
other session under the CS-US condition to bring their avoid-
ance responses back to the pre-drug level. These two retrain-
ing sessions also ensured that all groups had a comparable level 
of avoidance responding before the aripiprazole challenge test, 
which occurred one day after the 2nd retraining session. On the 
challenge day, all rats were injected with aripiprazole at 1.5 mg/ 
kg and tested for avoidance performance in the CS-only condi-
tion (30 trials) 60 min later. 
Phase 3: quinpirole-induced hyperlocomotion test. Two days after 
the aripiprazole challenge test in CAR, all rats were first habitu-
ated to the locomotor activity apparatus for two days (30 min/
day), with the second day preceded by saline injection prior to 
putting them into the test chambers. One day later, they were 
injected with quinpirole (1.0 mg/kg, sc) and immediately placed 
in the test apparatus for 120 min. Locomotor activity (number of 
photobeam breaks) was measured in 10-minute blocks through-
out the entire 120-minute test period. 
Experiment 2: Effect of repeated aripiprazole 
treatment on the PCP-induced hyperlocomotion 
This experiment examined how repeated aripiprazole (3.0, 10.0, 
30.0 mg/kg, sc) treatment affects the PCP-induced hyperloco-
motion. It was designed to examine the generalizability of aripip-
razole sensitization across different tests of antipsychotic activ-
ity. The entire experiment was comprised of the following three 
phases: Phase 1: five days of repeated aripiprazole testing; phase 
2: aripiprazole challenge test; and phase 3: quinpirole-induced hy-
perlocomotion test. Figure 1 summarizes the entire experimen-
tal procedure and groups at different phases of the experiment. 
Phase 1: Five days of repeated aripiprazole testing. Thirtytwo 
rats were randomly assigned to one of five groups: VEH+VEH 
(vehicle+saline, n=6), VEH+PCP (vehicle + PCP 3.20 mg/kg, 
n=6); ARI 3.0+PCP (ARI 3.0 mg/kg + PCP 3.20 mg/kg, n=6), ARI 
10.0+PCP (ARI 10.0 mg/kg + PCP 3.20 mg/kg, n=7) and ARI 
30.0+PCP (ARI 30.0 mg/kg + PCP 3.20 mg/kg, n=7). All rats were 
first handled and habituated to the locomotor activity appara-
tus for two days (30 min/day). On each of the next five consec-
utive days, they were first injected with vehicle (30% (v/v) di-
methylformamide and 2% (v/v) glacial acetic acid in water), ARI 
3.0, 10.0, 30.0 mg/kg and then immediately placed in the boxes 
for 30 min. At the end of the 30-minute period, they were taken 
out and injected with vehicle (saline) or PCP (3.20 mg/kg, sc) and 
placed back in the boxes for another 60 min. Locomotor activity 
(number of photobeam breaks) was measured in 5 min intervals 
throughout the entire 90-minute testing session. 
Phase 2: Aripiprazole challenge test. Two days after the last (5th) 
ARI test, all rats were returned to the locomotor activity boxes for 
one re-habituation session (30 min), followed by the aripiprazole 
challenge test one day later. On the challenge day, all rats were 
first injected with aripiprazole 3.0 mg/kg and then immediately 
placed in the locomotor activity boxes for 30 min. At the end of 
the 30-minute period, they were taken out and injected with PCP 
(3.20 mg/kg) and placed back in the boxes for another 60 min. 
Phase 3: quinpirole-induced hyperlocomotion test. Two days after 
the aripiprazole challenge test in CAR, all rats were first habituated 
to the locomotor activity apparatus for two days (30 min/day), 
with the second day preceded by saline injections prior to habit-
uation. One day later, they were injected with quinpirole (1.0 mg/
kg, sc) and immediately placed in the test apparatus for 120 min. 
Locomotor activity (number of photobeam breaks) was measured 
in 10-minute blocks throughout the entire 120-minute test period. 
Statistical analysis 
All data were expressed as mean + standard error of the mean 
(SEM). Data from the five drug test sessions (e.g. avoidance re-
sponse and PCP-induced hyperlocomotion) were analyzed using 
a factorial repeated measures analysis of variance (ANOVA) with 
the between-subjects factor being drug group and the within-
subjects factor being test session, followed by posthoc least sig-
nificant difference (LSD) tests. Differences between groups on 
the specific drug test days, on the habituation day and on the 
challenge tests were analyzed using one-way ANOVAs, followed 
by post-hoc LSD tests. Differences between groups on the spe-
cific drug test days and on the challenge tests were analyzed 
using one-way ANOVAs, followed by post-hoc LSD tests. For all 
analyses, p≤0.05 was considered statistically significant and all 
data were analyzed using SPSS version 22. 
Results 
Experiment 1: Effect of repeated aripiprazole 
treatment on avoidance response 
Phase 1: Five days of repeated aripiprazole testing. Figure 2(a) 
shows the mean number of avoidance responses made by rats 
in the four groups on the last training (predrug) day and five 
drug test days. There was no group difference on the last train-
ing day (predrug) (F(3, 32)=0.141, p=0.935). Throughout the 
five drug test days, aripiprazole increased its suppression of 
avoidance response progressively but not dose-dependently. 
Repeated measures ANOVA revealed a main effect of group 
(F(3,32)=159.834, p<0.001), day (F(4,128)=13.539, p<0.001), and 
a significant group×day interaction (F(12,128)=2.797, p=0.002). 
Post-hoc LSD tests show that all three ARI groups made sig-
nificantly fewer avoidance responses than the VEH group (all 
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ps<0.001), but the three ARI groups did not differ from each 
other (all ps>0.283). One-way ANOVA on each test day revealed 
that all three ARI groups had significantly lower avoidance than 
the VEH group on all five days (all ps<0.001). Additionally, on 
day 1, the ARI 30.0 group showed lower avoidance than the ARI 
3.0 group (p=0.002). 
Phase 2: Aripiprazole challenge test. Figure 2(b) shows the num-
ber of avoidance responses on the retraining day (predrug day) 
and the aripiprazole challenge day. No significant group differ-
ence was detected on the predrug day (F(3,32)=0.913, p=0.446). 
However, on the challenge day when all rats were injected with 
aripiprazole 1.5 mg/kg, the three ARI (3.0, 10.0, and 30.0 mg/kg) 
groups made fewer avoidance responses than the VEH group, 
indicating a sensitization effect. One-way ANOVA confirmed a 
main effect of group (F(3,32)=4.276, p=0.012). Post-hoc LSD tests 
showed that all three ARI groups were significantly different from 
the VEH group (p=0.004, 0.018, and 0.005 for ARI 3.0, 10.0, and 
30.0), although the three ARI groups did not differ significantly 
from each other (all ps>0.559). 
Phase 3: Quinpirole-induced hyperlocomotion test. To test 
whether the D2/3 receptor system was involved in aripiprazole 
sensitization, we tested quinpirole-induced locomotor activity in 
rats that were pretreated with ARI (three ARI groups) or vehicle. 
This test was conducted two days after the aripiprazole challenge 
test. As shown in Figure 3(a), quinpirole at 1.0 mg/kg increased 
motor activity during the 120-minute test period, with a higher 
motor activity found in the aripiprazole pretreated rats than the 
VEH pretreated ones. Repeated measures ANOVA revealed a sig-
nificant main effect of group (F(3,32)=5.134, p=0.005), timeblock 
(F(11,352)=127.823, p<0.001), and a significant group×block in-
teraction (F(33,352)=3.169, p<0.001). Post-hoc LSD tests show 
that the ARI 10.0 and ARI 30.0 groups made significantly more 
activity than the VEH (ps<0.020) and ARI 3.0 groups (ps<0.008); 
but the ARI 3.0 and VEH groups did not differ significantly from 
each other (p=0.659). One-way ANOVA with post-hoc LSD 
tests revealed that the ARI 10.0 group on the last six 10-minute 
blocks (70–120 min, all ps<0.037), and ARI 30.0 group on 2nd–
9th 10-minute blocks (20–90 min, all ps<0.039) had significantly 
higher motor activity than the VEH group, while ARI 10.0 group 
on the last eight 10-min blocks (50–120 min, all ps<0.040) and 
ARI 30.0 group on 2nd–9th 10-minute blocks (20–90 min, all 
ps<0.016) had significantly higher motor activity than the ARI 
3.0 group. 
Similarly, there was also a main effect of group on the total 
motor activity in 120 min (Figure 3(b), F(3,32)=5.134, p=0.005)). 
Post-hoc LSD tests showed that the ARI 10.0 and ARI 30.0 
groups had significantly higher motor activity than the VEH 
group (p=0.019 and 0.014, respectively), and the ARI 3.0 group 
(p=0.007 and 0.005, respectively). These findings suggest that 
repeated aripiprazole treatment induced an increase in D2/3 re-
ceptor- mediated function dose-dependently, which may serve 
as one mechanism for aripiprazole sensitization in CAR. 
Experiment 2: Effect of repeated aripiprazole 
treatment on PCP-induced hyperlocomotion 
Phase 1: Five days of repeated aripiprazole testing. Figure 4(a) 
shows the mean motor activity of the four groups of rats dur-
ing the 30-min period before PCP or vehicle injection through-
out the 5 days of drug testing. Repeated measures ANOVA re-
vealed a main effect of group (F(4,27)=18.538, p<0.001), day 
(F(4,108)=47.761, p<0.001), and significant group×day interac-
tion (F(16,108)=6.973, p<0.001). Post-hoc LSD tests revealed that 
the four PCP-treated groups had significantly lower motor activ-
ity than the VEH+VEH group (all ps≤0.001), mainly on Days 2–5. 
Figure 2. Repeated aripiprazole treatment increased avoidance response disruption and sensitivity to aripiprazole re-exposure. Number of avoid-
ance responses made by the rats from the three aripiprazole treatment groups (ARI 3.0, 10.0, and 30.0 mg/kg) and the vehicle group (VEH) on the 
last training (predrug) day and throughout the five drug test days (a), and on the aripiprazole (1.5 mg/kg) challenge test (b) are expressed as mean 
+ standard error of the mean (SEM). *p<0.05, **p<0.01, ***p<0.001 relative to VEH group; #p<0.05 for comparison to the ARI 3.0 group.  
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Figure 3. Quinpirole-induced locomotor activity in 12 10-minute blocks (a) or in 120 min (b) in the quinpirole-induced hyperlocomotion test. The 
test was conducted two days after the last aripiprazole (ARI) challenge test. All rats were injected with quinpirole (1.0 mg/kg, subcutaneously (sc)) and 
then measured for motor activity for 120 min. All data are expressed as mean + standard error of the mean (SEM) in 12 10-minute blocks. *p<0.05, 
**p<0.01 for comparison to the vehicle (VEH) group; #p<0.05, ##p<0.01 for comparison to the ARI 3.0 group.  
Figure 4. Effect of repeated aripiprazole (ARI 3.0, 10.0 and 30.0 mg/kg) treatment on phencyclidine (PCP)-induced hyperlocomotion across the five 
test days (n=6–7/group). Locomotor activity in the 30 min before vehicle(VEH) or PCP injection (a) and 60 min after PCP injection (b) are expressed 
as mean + standard error of the mean (SEM) for each group. **p<0.01, ***p<0.001 relative to the VEH+VEH group; #p<0.05, ##p<0.01, ###p<0.001 
relative to the VEH+PCP group.   
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Figure 4(b) shows the mean motor activity of the five groups 
of rats during the 60-minute period after PCP or vehicle injec-
tion throughout the five days of drug testing. Two-way repeated 
measures ANOVA revealed a significant main effect of group 
(F(4,27)=20.641, p<0.001), day (F(4,108)=4.214, p=0.003), and 
a significant group×day interaction (F(16,108)=6.786, p<0.001). 
Post-hoc LSD tests revealed that the three ARI+PCP (ARI 3.0, 
10.0, and 30.0 +PCP) groups exhibited significantly lower mo-
tor activity compared to the VEH+PCP group (all ps<0.001). The 
VEH+PCP group had significantly higher motor activity than the 
VEH+VEH group (p<0.001), indicating a strong psychomotor ac-
tivation effect of this dose of PCP. One-way ANOVA on each 
test day revealed that the all three ARI (3.0, 10.0 and 30.0+PCP) 
groups had significantly lower activity than the VEH+PCP group 
on Days 2–5 (all ps<0.016). In addition, the ARI 10.0+PCP group 
also had significantly lower motor activity than VEH+PCP group 
(p=0.002) and ARI 3.0+PCP group (p=0.004) on Day 1. 
Phase 2: Re-habituation and aripiprazole challenge test. On the 
re-habituation day, rats previously treated with VEH+PCP or 
ARI 30.0+PCP had lower motor activity than other groups (Fig-
ure 5(a)). One-way ANOVA showed a significant effect of group 
(F(4,27)=6.870, p=0.001). Post-hoc test showed that the two 
ARI (3.0 and 10.0 mg/kg) groups (all ps<0.041) and VEH+VEH 
group (p=0.003) had significantly higher motor activity than the 
VEH+PCP group, and the ARI 3.0+PCP group had higher mo-
tor activity than the ARI 10.0+PCP (p=0.039) and ARI 30.0+PCP 
groups (p<0.001). In addition, the ARI 30.0+PCP group showed 
significantly lower motor activity relative to the VEH+VEH group 
(p=0.004). These results suggest that concurrent 3.0 and 10.0 
mg/kg ARI treatment with PCP prevented the PCP-withdrawal- 
induced decrease in spontaneous motor activity. 
On the ARI sensitization challenge test, in the first 30 min 
(Figure 5(b)), the three ARI groups had lower motor activity 
than the vehicle group. One-way ANOVA revealed a main ef-
fect of group (F(4,27)=4.024, p=0.011). The ARI 10.0+PCP group 
had significantly lower motor activity than the VEH+PCP group 
(p=0.011), and both ARI 10.0+PCP and ARI 30.0+PCP groups 
had significantly lower motor activity than the VEH+VEH group 
(p=0.001, 0.015, respectively). In the 60-minute test period after 
PCP injection (Figure 5(c)), one-way ANOVA revealed a main ef-
fect of group (F(4,27)=7.678, p<0.001). Post hoc comparisons re-
vealed that the all three ARI (ARI 3.0, 10.0 and 30.0+PCP) groups 
had significantly lower motor activity than the VEH+PCP group 
(all ps≤0.003), indicating a ARI sensitization effect. 
Collectively, results from this experiment provided further ev-
idence of aripiprazole sensitization. Similar to aripiprazole sensi-
tization observed in the conditioned avoidance test (experiment 
1), this effect was manifested as an enhanced inhibition of PCP-
induced hyperlocomotion (an index of antipsychotic activity) in 
the ARI treated animals. 
Phase 3: Quinpirole-induced hyperlocomotion test. To test 
whether the D2/3 receptor system was involved in aripiprazole 
sensitization, we tested quinpirole-induced locomotor activ-
ity in rats tested in the PCP model. This test was conducted 
two days after the ARI challenge test in PCP model. As shown 
in Figure 6(a), quinpirole at 1.0 mg/kg increased motor activity 
during the 120-minute test period, with a higher motor activity 
found in the ARI 30.0+PCP pretreated rats than the VEH+PCP 
pretreated ones. Repeated measures ANOVA revealed a signif-
icant main effect of group (F(4,27)=3.794, p=0.014), time-block 
(F(11,297)=43.61, p<0.001), and a significant group×block inter-
action (F(44,297)=1.926, p=0.001). Post-hoc LSD tests show that 
Figure 5. Locomotor activity during the 30-minute test period on the rehabituation day (a), 30-minute test period before phencyclidine (PCP) injec-
tion (b) and the 60-minute test period after PCP injection (c) on the aripiprazole (ARI) challenge test day. *p<0.05, **p<0.01, ***p<0.001 relative to the 
vehicle (VEH)+VEH group; #p<0.05, ##p<0.01, ###p<0.001 relative to the VEH+PCP group; #p<0.05, ###p<0.001 relative to the ARI 3.0+PCP group. 
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the ARI 30.0+PCP group was significantly more active than the 
VEH+VEH group (p=0.002), the VEH+PCP group (p=0.014), and 
the ARI 3.0+PCP group (p=0.005); but the ARI 3.0+PCP and ARI 
10.0+PCP groups did not differ significantly from the VEH+PCP 
group (all ps>0.524). One-way ANOVA with post-hoc LSD tests 
revealed that the ARI 30.0+PCP group had significantly higher 
motor activity than the VEH+PCP group on the 3rd–9th 10-min-
ute blocks (30–90 min, all ps<0.039), VEH+VEH group on all 12 
10-minute blocks (all ps<0.035), and ARI 3.0+PCP group at 10, 
40–120 min points (ps<0.043), and ARI 10.0+PCP group at the 
10 and 60 min points (ps<0.015), while the ARI 10.0 group had 
significantly higher motor activity than the ARI 3.0 group at the 
90 and 110 min points (all ps<0.049). 
Similarly, the group difference on the total motor activity in 
120 min was also significant (Figure 6(b), F(4,27)=3.794, p=0.014). 
Post-hoc LSD tests showed that the ARI 30.0+PCP group was 
significantly different from the VEH+VEH group (p=0.002), 
VEH+PCP group (p=0.014), ARI 3.0+PCP group (p=0.005), and 
ARI 10.0+PCP group (p=0.050). These data are consistent with 
those reported in experiment 1 and suggest that repeated ar-
ipiprazole treatment induced an increase in D2/3 receptor-medi-
ated function dose-dependently, a change that may partially un-
derlie aripiprazole sensitization. 
Discussion 
Aripiprazole is an atypical antipsychotic drug with mechanisms 
of action distinctive from the more widely used atypicals, such 
as clozapine, risperidone, olanzapine, and quetiapine. Aripipra-
zole shows high affinity for dopamine D2 receptors but as a par-
tial agonist rather than a full antagonist at these receptors (Ai-
hara et al., 2004; Burris et al., 2002; Kikuchi et al., 1995; Lawler 
et al., 1999; Shapiro et al., 2003). As a result, it acts as a D2 re-
ceptor agonist at receptor sites where dopaminergic transmis-
sion is significantly decreased while acting as an antagonist at 
other dopaminergic sites with normal or increased transmission, 
functioning as a dopamine activity stabilizer. In addition to the 
action of aripiprazole on dopamine receptors, this drug shows 
partial agonism at 5-HT1A receptors and antagonism at 5-HT2A 
receptors (Jordan et al., 2002; Kikuchi et al., 1995). In the pres-
ent study, we demonstrated that repeated aripiprazole treatment 
for five days caused an augmentation of its disruption of avoid-
ance responding and inhibition of PCP-induced hyperlocomo-
tion in a dose-dependent fashion. This effect was observed in 
both the induction phase and expression phase using two mea-
sures of sensitization (withinsubjects and between-subjects com-
parisons). Therefore, despite its novel mechanisms, aripiprazole 
induced a sensitized behavioral effect similar to those of other 
atypicals (e.g. olanzapine, risperidone, and asenapine). Further-
more, repeated aripiprazole treatment also increased sensitivity 
to quinpirole challenge, indicating an upregulation of D2/3-me-
diated neurotransmission. These findings reveal that aripiprazole 
shares a similar feature of sensitization with haloperidol, ase-
napine, olanzapine, and risperidone in behavioral tests of anti-
psychotic activity, and that this long-term effect is likely related 
to plastic changes in D2/3-receptors and other receptors that ar-
ipiprazole targets. 
Previous work has shown that acute aripiprazole treatment 
at 10 and 30 mg/kg significantly suppresses conditioned avoid-
ance response in rats (Hertel et al., 2005; Natesan et al., 2006). 
The present study extended this finding to show that repeated 
aripiprazole treatment intensifies this suppression over time and 
this intensification was long-lasting and could be detected in a 
later drug challenge test, as rats previously treated with aripip-
razole showed significantly lower avoidance than the drug-na-
ive rats. Similarly in the PCP-induced hyperlocomotion test, our 
finding on the acute aripiprazole effect is consistent with a pre-
vious report showing that aripiprazole reduces PCP-induced in-
Figure 6. Quinpirole-induced locomotor activity in 12 10-min blocks (a) or in 120 min (b) in the quinpirole-induced hyperlocomotion test. The test 
was conducted two days after the last aripiprazole (ARI) challenge test. All rats were injected with quinpirole (1.0 mg/kg, subcutaneously (sc)) and 
then measured for motor activity for 120 min. All data are expressed as mean + standard error of the mean (SEM) in 12 10-minute blocks. PCP: phen-
cyclidine; VEH: vehicle. *p<0.05, **p<0.01, ***p<0.001 for comparison to the VEH+VEH group; #p<0.05, ##p<0.01 for comparison to the VEH+PCP 
group; $p<0.05, $$p<0.01 for comparison to the ARI 3.0+PCP group; &p=0.05 for comparison to the ARI 10.0+PCP group.   
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crease in locomotor activity at 1–30 mg/kg (Nordquist et al., 
2008). Again, the novel finding is on the sensitization effect of 
aripiprazole that manifested as the progressively enhanced sup-
pression of PCP-induced hyperlocomotion during the induction 
phase (Figure 4(b)), and an enhanced sensitivity to aripiprazole 
challenge in the expression phase (Figure 5(b) and (c)). To our 
knowledge, this is the first report on the repeated behavioral ef-
fects of aripiprazole in these two models. The fact that the same 
sensitization effect was found in two distinct behavioral assess-
ments supports the generalizability of such an effect. Because 
aripiprazole at the doses used here induces approximately 65–
85% D2 occupancies in rodents (Natesan et al., 2006), a level 
which is commonly found in human volunteers treated with ad-
equate doses of aripiprazole (Yokoi et al., 2002). Thus, it seems 
likely that the doses we used were sufficient and clinically rele-
vant, and the sensitization effect of aripiprazole may reflect an 
intrinsic feature of this drug. 
This intrinsic feature does not distinguish aripiprazole from 
other atypical antipsychotic drugs at least at the behavioral level 
since most other antipsychotic drugs, except for clozapine, also 
induce a sensitization effect in these two widely used behavioral 
tests (Feng et al., 2013; Li et al., 2012; Mead and Li, 2010; Qiao 
et al., 2013; Qin et al., 2013; Swalve and Li, 2012; Zhang and Li, 
2012). Clozapine is the only drug that induces a tolerance ef-
fect in these tests (Feng et al., 2013; Li et al., 2010, 2012). On 
this front, it can be inferred that aripiprazole has a clinical pro-
file similar to that of olanzapine, risperidone, and asenapine but 
different from that of clozapine. As a basic principle in psycho-
pharmacology, the demonstration of aripiprazole sensitization 
further supports the notion that once an organism is exposed 
to an antipsychotic drug, this drug experience stays with it for 
a long period of time and may have a drug memory-like char-
acteristic. Clinically, antipsychotic sensitization has been consid-
ered as a behavioral mechanism underlying the therapeutic ef-
fects of antipsychotic treatment (Kapur et al., 2006; Sun et al., 
2009), as it matches with the early onset and progressive im-
provement pattern of antipsychotic response in patients (Agid 
et al., 2003). Thus, it can be said that the gradual improvement 
of psychotic symptoms over time is due to the drug-induced 
sensitization process that intensifies the behavioral effects of 
the drug. However, antipsychotic sensitization may also under-
lie the drug-induced extrapyramidal motor syndrome and tar-
dive dyskinesia (Turrone et al., 2005), an idea also supported by 
the findings that acute or repeated administration of many an-
tipsychotic drugs, including aripiprazole, causes an impairment 
of motor function or coordination (Barnes et al., 1990; Burda et 
al., 2011; Nordquist et al., 2008). At this point, the clinical signif-
icance of antipsychotic sensitization in general and aripiprazole 
sensitization in particular is still not clear. From this perspective, 
understanding the clinical significance of aripiprazole sensitiza-
tion and associated neurobiological mechanisms may help en-
hance our understanding of the behavioral and neurobiological 
mechanisms of clinical antipsychotic response. 
One interesting finding is that the VEH+PCP group had sig-
nificantly lower spontaneous motor activity than the VEH+VEH 
group on the rehabituation day when all rats were placed in the 
test boxes drug-free for 30 min (Figure 5(a)), suggesting a PCP 
withdrawal-induced decrease in motor activity. This effect has 
not been reported before (Qin et al., 2013) and may reflect PCP 
withdrawal- induced anxiety or depression which is well known 
in the literature (Audet et al., 2007; Baird et al., 2008; Noda et 
al., 1995; Renoir et al., 2012; Spielewoy and Markou, 2003). In-
terestingly, concurrent ARI treatment at 3 and 10 mg/kg allevi-
ated this effect. Similar findings have been reported with clo-
zapine and risperidone (Grayson et al., 2007; Qiao et al., 2001). 
ARI at 30 mg/kg did not exhibit this effect, possibly due to the 
qualitative and quantitative differences in brain plasticity be-
tween this dose of ARI and other doses. For example, Peselmann 
et al. (2013) found that the gene expression of gamma-amino-
butyric acid (GABA) transmembrane transporters Slc6a1 (Gat1) 
and Slc6a11 (Gat3) in the hippocampus, caudate nucleus and pu-
tamen, and cerebral cortex were increased by a lower dose (10 
mg/kg) rather than a higher dose (40 mg/kg) of ARI (Peselmann 
et al., 2013), and Zocchi et al. (2005) demonstrated that aripip-
razole at lower dose (0.3 mg/ kg) but not higher doses (3 and 
30 mg/kg) produced a significant increase in extracellular levels 
of dopamine in the mouse frontal cortex. Future studies should 
attempt to replicate this effect and the effect of PCP withdrawal-
induced decrease in motor activity to further understand their 
neurobiological mechanisms. 
At the receptor level, aripiprazole-induced sensitization 
seems partially to be accompanied by drug-induced functional 
changes in dopamine D2/3 receptors. This was revealed in the 
quinpirole-induced hyperlocomotion test, a validated behav-
ioral assay of D2-mediated neurotransmission. Aripiprazole-pre-
treated rats had significantly higher motor activity than the cor-
responding vehicle rats under the quinpirole challenge. Seeman 
(2008) also found that one week of aripiprazole treatment signif-
icantly increased the ratio of D2
High
 receptors in the striatum of 
adult rats, an effect that is often associated with dopamine su-
persensitivity (Seeman et al., 2005). Our current finding is similar 
to our previously reported risperidone-induced sensitization, as 
risperidonepretreated rats were also more active than the cor-
responding vehicle rats when challenged with quinpirole (Gao 
and Li, 2013). In addition to dopamine D2/3 receptors, serotonin 
5-HT2A/2C receptor systems may also play important roles in an-
tipsychotic sensitization. Recently, we showed that pretreatment 
of quinpirole or 2,5-dimethoxy-4-iodo-amphetamine (DOI, a se-
lective 5-HT2A/2C agonist) attenuated the magnitude of olanzap-
ine sensitization effect (Li et al., 2010). In the case of aripiprazole 
sensitization, the neuroreceptor mechanisms may involve other 
receptors in addition to dopamine D2/3. First, aripiprazole has 
additional high affinity for several 5-HT receptors (e.g. 5-HT1A, 
5-HT2A, 5-HT2B and 5-HT7), α1-adrenergic and H1-histamine re-
ceptors, and functions as an inverse agonist at 5-HT2B recep-
tors and a partial agonist at 5-HT2A, 5-HT2C, D3, and D4 receptors 
(Shapiro et al., 2003). It is conceivable that five days of repeated 
aripiprazole treatment could also have altered the functions of 
these receptors in addition to alteration of D2 receptors. Second, 
Inoue et al. (1997) showed that repeated administration of ar-
ipiprazole at 12–100 mg/kg dose range for three weeks did not 
induce any up-regulation of dopamine D2 mRNA expression in 
the striatum. Tadokoro et al. (2012) reported that aripiprazole at 
1.5 mg/kg/day via minipump for 14 days does not cause an in-
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crease in D2 binding sites and dopamine supersensitivity in adult 
rats. These findings suggest that D2 receptor-mediated neuro-
transmission might not be critical in support of aripiprazole’s 
long-term effect. We speculate that the observed enhanced sen-
sitivity to quinpirole challenge in aripiprazole-treated rats may 
reflect drug-induced changes on other receptors (e.g. 5-HT1A, 
5-HT2A, 5-HT2B) in other parts of the brain (e.g. medial prefron-
tal cortex). Finally, aripiprazole at 3.0 mg/kg did not induce any 
changes in quinpirole-induced hyperlocomotion in motor activ-
ity in both experiments (Figure 3(b) and Figure 6(b)): however, 
it clearly induced a sensitization effect (Figure 2(b) and Figure 
5(c)), suggesting that dopamine D2/3 might be just one of many 
mechanisms involved in aripiprazole sensitization. 
In summary, aripiprazole is a novel antipsychotic drug which 
shares a similar repeated behavioral profile with most antipsy-
chotic drugs (e.g. olanzapine, risperidone, asenapine) on the ba-
sis of the findings that its repeated treatment caused a sensi-
tization effect in both the induction and expression phases of 
the CAR and PCPinduced hyperlocomotion tests. One poten-
tial receptor mechanism responsible for its sensitization effect 
is the functional changes in dopamine D2/3 system. Future work 
should explore other molecular mechanisms and identify the rel-
evant neurochemical systems and various forms of neuroplasti-
city (Allen et al., 2011; Konradi and Heckers, 2001; Lieberman et 
al., 2008; Meltzer et al., 1989).   
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